Understanding the time course of pharmacological effect: A PKPD approach

British Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2011, Pages 815-823

  Wright, Daniel F B ^a   Winter, Helen R ^a,b   Duffull, Stephen B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

Author keywords

Population pharmacokinetic pharmacodynamic models

Indexed keywords

BLOOD CLOTTING FACTOR; DABIGATRAN; DICLOFENAC; FENTANYL; SIMVASTATIN; SOTALOL; THEOPHYLLINE; TUBOCURARINE CHLORIDE; WARFARIN;

ARTICLE; BINDING KINETICS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; DRUG RECEPTOR BINDING; EQUILIBRIUM CONSTANT; HALF LIFE TIME; HUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; SECOND MESSENGER; STEADY STATE; STOICHIOMETRY;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; POPULATION; RESEARCH; TIME FACTORS;

EID: 79955825778     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03925.x     Document Type: Article

References (38)

1. Leake CD. The scientific status of pharmacology. Science 1961; 134: 2069-79.
2. Reidenberg MM. Clinical pharmacology: the scientific basis of therapeutics. Clin Pharmacol Ther 1999; 66: 2-8.
3. Danhof M, de Jongh J, De Lange ECM, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 2007; 47: 357-400.
4. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 2000; 40: 67-95.
5. Duffull SB, Wright DFB, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol 2011; DOI: 10.1111/j.1365-2125.2010.03891.x.
6. Bonate PL. Recommended reading in population pharmacokinetic pharmacodynamics. AAPS J 2005; 7: E363-73.
7. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, Girard P, Laffont CM, Mentre F. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-34.
8. Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB. The time course of drug effects. Pharm Stat 2009; 8: 176-85.
9. Minto C, Schnider T. Expanding clinical applications of population pharmacodynamic modelling. Br J Clin Pharmacol 1998; 46: 321-33.
10. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004; 38: 1702-6.
11. Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-53.
12. Jacqmin P, Snoeck E, van Schaick E, Gieschke R, Pillai P, Steimer J, Girard P. Modellling response time profile in the absence of drug concentrations: definition and performance evaluation of the PK-PD model. J Pharmacokinet Pharmacodyn 2007; 34: 57-85.
13. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic - pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511-28.
14. Atkinson AJ Jr, Lalonde RL. Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview. Clin Pharmacol Ther 2007; 82: 3-6.
15. Holford NH, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982; 16: 143-66.
16. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25: 358-71.
17. Atkinson AJ. Clinical Pharmacokinetics. In: Principles of Clinical Pharmacology, 2nd edn, eds Atkinson A, Abernethy D, Daniels C, Dedrick R, Markey S. New York, NY: Academic Press, 2007; 11-23.
18. Wright DFB, Begg EJ. The 'apparent clearance' of free phenytoin in elderly vs. younger adults. Br J Clin Pharmacol 2010; 70: 132-38.
19. Sharp CF, Gardiner SJ, Jensen BP, Roberts RL, Troughton RW, Lainchbury JG, Begg EJ. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure. Pharmacogenomics J 2009; 9: 175-84.
20. Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007; 29: 619-25.
21. Bourne HR, von Zastrow M. Drug Receptors and Pharmacodynamics. In: Basic and Clinical Pharmacology, 8th edn, ed. Katzung BG. New York, NY: McGraw-Hill, 2001; 9-34.
22. Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 2006; 33: 227-79.
23. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-18.
24. Beeler D, Rosenberg R, Jordan R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-13.
25. Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527-37.
26. Auler Júnior JO, Espada EB, Crivelli E, Quintavalle TB, Kurata A, Stolf NA, Issy AM, Paschoa OE, Danhof M, Breimer DD, Chamone DA, Santos SR. Diclofenac plasma protein binding: PK-PD modelling in cardiac patients submitted to cardiopulmonary bypass. Braz J Med Biol Res 1997; 30: 369-74.
27. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963-78.
28. Yassen A, Olofsen E, Romberg R, Sarton E, Teppema L, Danhof M, Dahan A. Mechanism-based PK/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007; 81: 50-8.
29. Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol 1997; 37: 799-809.
30. Hornestam B, Jerling M, Karlsson MO, Held P, Group DAT. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol 2003; 58: 747-55.
31. Sharma A, Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 1998; 45: 229-39.
32. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406-19.
33. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-78.
34. Faltaos DW, Urien S, Carreau V, Chauvenet M, Hulot JS, Giral P, Bruckert E, Lechat P. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol 2006; 20: 321-30.
35. Cleton A, de Greef HJ, Edelbroek PM, Voskuyl RA, Danhof M. Application of a combined 'effect compartment/indirect response model' to the central nervous system effects of tiagabine in the rat. J Pharmacokinet Biopharm 1999; 27: 301-23.
36. Holford NH. Rational warfarin dosing: a pharmacokinetic-pharmacodynamic analysis. Clin Pharmacol Ther 1986; 39: 199.
37. O'Reilly RA, Aggeler PM, Leong LS. Studies on the coumadin anticoagulant drugs: the pharmacodynamics of warfarin in man. J Clin Invest 1963; 42: 1542-51.
38. O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation 1968; 38: 169-77.